/Investor DB

Forepont Capital Partners — Full Portfolio

17 tracked investments · listed companies and verified rows first

Resteraresterasleep.com✓ verified

Restera develops neurostimulation and sleep therapy medical devices, bringing over 75 years of combined expertise in these areas with 100+ FDA approvals.

Deep TechHardwareHealthtechMedical Devices

Rick O'Connor(CEO)

Co-investorsSupermoon CapitalAphelion CapitalDns CapitalGreatPoint Ventures

AlterDiagalterdiag.comin𝕏Jan 2025

AlterDiag is a diagnostics company founded by executives with backgrounds in immunology R&D and business strategy.

BiotechDigital HealthHealthtechMedical DevicesParis, FR

Karine(Founder)Cédric(Founder)

Ansell A/Sansellatx.comin

Ansella Therapeutics develops novel vaginal formulations for women's health conditions using biomimetic materials science and biomedical engineering, focused on treating menopause, vaginal dryness, dyspareunia, vaginal mucositis, endometriosis, uterine fibroids, and vaginal infections.

BiotechFemTechMedical DevicesAustin, US

Basecamp Vascularbasecampvascular.comin𝕏

BCV Systems develops a mechatronic guidewire system using shape memory alloy actuators to optimize navigation during minimally invasive endovascular procedures for stroke treatment and other vascular interventions.

Deep TechHealthtechMedical DevicesParis, FR

Dr Raphaël Blanc(Co-Founder, President)Jérôme Szewczyk(Co-Founder)inJean-Baptiste Cazeneuve(Co-Founder, CTO)in

Bay Bridge Digitalbaybridgedigital.cominJun 2018

BayBridgeDigital is a Salesforce consulting firm that helps retailers, healthcare, real estate, education, and hospitality companies with digital transformation through CRM implementation, data management, and cloud platform integration.

Data & InfrastructureEnterprise SoftwareSaaSNew York, US

Alain Attias(Founder)inGuy Jerusalmi(Executive Officer)

Becare Linkbecarelink.comin

BeCareLink builds AI-enhanced mobile platforms for remote neurological assessments, allowing patients to monitor their neurological health from home while helping clinicians and researchers track disease progression.

AI & Machine LearningDigital HealthHealthtech

Lawrence Rubin(Co-founder)Charisse D. Litchman(Co-founder)

Biospeediabiospeedia.comin𝕏

BioSpeedia is a biotechnology company that develops and produces rapid lateral-flow diagnostic tests for infectious diseases, including tests for bacterial meningitis and SARS-CoV-2.

BiotechHealthtechMedical Devices

Evelyne Begaud(Co-founder & President)Yves Germani(Co-founder & Chief Scientific Officer)in

Blackrock Neurotechblackrockneurotech.comin𝕏

Blackrock Neurotech develops a neurotechnology platform, including brain-computer interface systems, aimed at improving patient lives and treating neurological conditions.

BiotechDeep TechMedical Devices

Florian Solzbacher(Co-Founder & CSO)inMarcus Gerhardt(Co-Founder & CEO)inThomas Thiele(CFO)in

BoardChristian Angermayer(Co-Chairman)Tim Sievers(Co-Chairman)

Co-investors2050 CapitalCatalio Capital Management, LPPresight CapitalWPSS InvestmentsTether

Exeliom Biosciencesexeliombio.cominOct 2025

Exeliom Biosciences is a biotechnology company developing biotherapies, with work in areas such as inflammatory bowel disease (Crohn's and colitis).

BiotechDeep TechDigital HealthMedical DevicesParis, FR

Harry Sokol(Scientific Co-founder)in

Co-investorsBpifranceAgoranovAuriga PartnersUI Investissement

GPN Vaccinesgpnvaccines.comJun 2024 · $18M

GPN Vaccines is a clinical-stage company developing vaccines against bacterial pathogens, including a vaccine to prevent pneumococcal disease.

BiotechHealthtechNew York, US

Timothy Hirst(Executive Officer, Director)James Selkirk(Executive Officer)in

Co-investorsKern Capital, LLCShearwater Capital

Invicta Medicalinvictamedical.com

Portola Valley, US

William Deihl(Executive Officer)Steven T. Kent(Executive Officer, Director)Harold Kent(Executive Officer, Director)

BoardJason Camm(Director)

Co-investorsAphelion CapitalEclipse VenturesGreatPoint Ventures

Okeirookeiro.cominApr 2025

Okeiro is a medical platform using predictive algorithms to monitor transplant and chronic disease patients.

AI & Machine LearningDigital HealthMedical Devices

Co-investorsRed River WestAlven

Precisionprecision.co𝕏Jan 2023 · $41M

Precision is an AI platform paired with operators who build, train, and run AI agents across a company's marketing, delivery, support, operations, and finance functions.

AI & Machine LearningEnterprise SoftwareSaaS

Matt Verlaque(Founder)in

Co-investorsRevUp Capital216 CapitalAlumni VenturesB CapitalB Capital GroupDraper Associates+3 more

Precision Neuroscienceprecisionneuro.ioin𝕏

Precision Neuroscience develops a minimally invasive, high-bandwidth brain-computer interface, including its Layer 7 cortical interface, initially aimed at helping people with paralysis control digital devices and robotics using their thoughts.

Deep TechDigital HealthHealthtechMedical DevicesNew York, US

Benjamin Rapoport(President, Chief Science Officer)inMichael Mager(Chief Executive Officer)inCraig Mermel(President and Chief Product Officer)inMIchael Kaswan(Chief Financial Officer)Konstantinos Alataris(President)inBenjamin Rapoport Michael Mager(Founder)

Co-investorsAlumni VenturesB Capital GroupB4 CapitalBasecamp FundDraper AssociatesPerridon Ventures+3 more

Synchronsynchron.comin𝕏May 2021

Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.

BiotechDeep TechMedical DevicesCampbell, US

Thomas James Oxley(Executive Officer, Director)Nicholas Opie(Founder)inThomas Oxley(Founder)inTom Oxley(Founder)

BoardRahul Sharma(Director)Alex Morgan(Director)in

Co-investorsAlumni VenturesARCH Venture PartnersID8 InvestmentsIn-Q-TelK2 GlobalKaleida Capital+15 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Ansella TherapeuticsEnquyst Technologies

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.